A kit for promoting drug penetration into the brain and repairing neurons and its application

By using Tween 80-coated SC79 or 740YP liposomes to enhance the brain-targeting small molecule compound delivery system, followed by the delivery of large molecule peptides, the problem of large molecule peptides being difficult to enter the brain has been solved, significantly improving the treatment effect of neurodegenerative diseases.

CN114681624BActive Publication Date: 2024-11-29ZHEJIANG UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202210369400.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-08
Publication Date
2024-11-29
Estimated Expiration
2042-04-08

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively improve the efficiency of large molecular weight peptides such as GDNF and exenatide entering the brain, resulting in poor treatment outcomes for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

Method used

Tween 80-coated SC79 or 740YP liposomes were used as brain-targeting small molecule compound delivery systems, followed by macromolecular peptide delivery systems to enhance the intrabrain transport efficiency of macromolecular peptides and open the blood-brain barrier by downregulating the expression of the tight junction protein Claudin-5.

Benefits of technology

It significantly increased the amount of macromolecular peptides such as GDNF and exenatide entering the brain parenchyma, improved the treatment effect of neurodegenerative diseases, especially the symptoms of Parkinson's disease and Alzheimer's disease, increased the expression levels of tyrosine hydroxylase and dopamine, and enhanced the treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure HDA0003587423690000011
    Figure HDA0003587423690000011
Patent Text Reader

Abstract

The present invention provides a kit and application for promoting brain penetration of drugs to repair neurons, wherein the kit is composed of a brain-targeted small molecule compound delivery system and a macromolecular polypeptide or a macromolecular polypeptide delivery system that enhances brain penetration. The kit provided by the present invention can promote the entry of macromolecular polypeptides and brain-targeted macromolecular polypeptide delivery systems into the brain. The kit of the present invention, in which the two are administered sequentially, has a better therapeutic effect than a single macromolecular polypeptide or a brain-targeted macromolecular polypeptide delivery system. The kit of the present invention can be used in the preparation of drugs for treating neurodegenerative diseases by opening the blood-brain barrier, improving brain penetration of drugs, increasing drug concentration at neuronal lesion sites, reducing neuroinflammation, and promoting neuronal regeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the pharmaceutical field, and relates to a kit for promoting drug penetration into the brain to repair neurons and its application. The kit enhances brain permeability through Tween 80-coated SC79 liposomes or Tween 80-coated 740YP liposomes, promotes macromolecular polypeptides or brain-targeted macromolecular polypeptide delivery systems to enter the brain, and can be used in the preparation of drugs for treating neurodegenerative diseases. Background Art

[0002] Neurodegenerative diseases are the gradual loss of neuronal structure or function in the brain, which worsens over time and eventually leads to cell death. Neurodegenerative diseases can be acute or chronic. The former include cerebral ischemia, brain injury, and epilepsy, while the latter include Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, different types of spinocerebellar ataxia, etc. The occurrence and development of neurodegenerative diseases are inseparable from age. Since there is no current method to reverse the progressive degeneration of neurons, these diseases are currently incurable. With the continuous decline in the birth rate, the aging trend will become increasingly serious. With the increase in the elderly population, the occurrence of neurodegenerative diseases will seriously affect people's health and quality of life, and at the same time bring huge economic burdens to society. Therefore, it is urgent to find effective prevention and treatment methods.

[0003] Parkinson's disease (PD) and Alzheimer's disease (AD) are the two most common neurodegenerative diseases, affecting 3-7% of people over 65 years old. The clinical motor symptoms of Parkinson's disease include bradykinesia, tremor and rigidity, and non-motor symptoms include anxiety, memory loss, depression, etc. Degeneration of substantia nigra neurons in the midbrain leads to a significant decrease in dopamine content in the striatum, and α-synuclein aggregation is the main pathological feature of PD. The clinical symptoms of Alzheimer's disease include memory impairment, aphasia, apraxia, agnosia, visual-spatial skill impairment, executive dysfunction, and personality and behavioral changes, which are characterized by global dementia. At present, the first-line drugs for PD and AD in clinical practice are mainly used to improve symptoms, not the root cause, and mainly relieve the patient's motor symptoms. It is a symptomatic treatment. So far, no ideal drug has been found to fundamentally prevent the further degeneration of the disease. Exenatide is a glucagon-like peptide-1 (GLP-1) agonist used to treat type 2 diabetes. Clinical trials have shown that exenatide can promote the survival of midbrain dopamine neurons and acetylcholinergic neurons in patients with PD and AD, and improve patients' motor symptoms such as bradykinesia, stiffness and postural instability, as well as symptoms such as memory impairment. Glial cell line-derived neurotrophic factor (GDNF) helps the differentiation and survival of midbrain dopamine neurons and promotes dopamine uptake. In recent years, a large number of preclinical and clinical trials have shown that GDNF can prevent the degeneration of substantia nigra and striatum neurons, induce neuronal regeneration, and greatly improve the motor symptoms and corresponding biochemical indicators of experimental animals and clinical patients. However, despite the excellent clinical trial results, GDNF, a 32KDa macromolecular polypeptide, is administered by direct injection into the striatum through surgery, which increases the risk of surgical complications.

[0004] In recent years, a series of progress has been made in the research of brain-targeted drug delivery systems. Receptor-ligand binding to achieve transcellular transport of carriers is a common technical means, but the efficiency of drug entry into the brain is still very low. Opening the blood-brain barrier can achieve efficient drug entry into the brain. The PI3K agonist SC79 can downregulate the expression of tight junction protein Claudin-5 and temporarily open the blood-brain barrier. However, systemic administration of free drugs prevents the drugs from exerting their maximum effect at the target site. Tween 80-coated SC79 liposomes can well overcome the above shortcomings, target brain endothelial cells, and play a greater role in opening the blood-brain barrier. Compared with free SC79 combined with peptide liposome treatment, Tween 80-coated SC79 liposomes can open the blood-brain barrier to a greater extent, allowing peptide liposomes to efficiently enter the brain. Animal experimental results show that the motor symptoms of PD mice have been better restored and the expression level of tyrosine hydroxylase is higher. Summary of the invention

[0005] The purpose of the present invention is to provide a kit for promoting brain penetration of drugs to repair neurons, which is composed of a brain-targeted small molecule compound delivery system for enhancing brain penetration and a large molecule polypeptide, or a brain-targeted small molecule compound delivery system for enhancing brain penetration and a large molecule polypeptide delivery system. The brain-targeted small molecule compound delivery system is used before the large molecule polypeptide or the large molecule polypeptide delivery system, and the two are used sequentially to increase the amount of the latter entering the brain.

[0006] The brain-targeted small molecule compound delivery system with enhanced brain penetration includes but is not limited to SC79 liposomes, 740YP liposomes or surface-modified liposomes.

[0007] The delivery system is preferably Tween 80-coated SC79 liposome or Tween 80-coated 740YP liposome.

[0008] The macromolecular polypeptide refers to exenatide, or a polypeptide that repairs neuronal damage, such as a neurotrophic factor that can activate transmembrane receptor tyrosine kinase, including but not limited to glial cell-derived neurotrophic factor or brain-derived neurotrophic factor.

[0009] The Tween 80-coated SC79 liposomes or Tween 80-coated 740YP liposomes are selected from liposomes in which 1,2-dioleoyl-sn-glycero-3-phosphocholine or (2,3-dioleoyl-propyl)-trimethylammonium chloride or 12-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 is combined with cholesterol. Preferably, 1,2-dioleoyl-sn-glycero-3-phosphocholine or (2, 3-dioleoyl-propyl)-trimethylammonium chloride or 12-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000: cholesterol = 6:1-4:1 (mass ratio).

[0010] The macromolecular polypeptide delivery system is a macromolecular polypeptide liposome or a macromolecular polypeptide liposome modified by Tween 80.

[0011] The macromolecular polypeptide liposomes and Tween 80 modified macromolecular polypeptide liposomes are selected from liposomes composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine or (2,3-dioleoyl-propyl)-trimethylammonium chloride or 12-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 and cholesterol, preferably 1,2-dioleoyl-sn-glycero-3-phosphocholine or (2,3-dioleoyl-propyl)-trimethylammonium chloride or 12-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000: cholesterol = 6:1 = 4:1 (mass ratio).

[0012] Another object of the present invention is to provide the use of the kit in the preparation of drugs for treating neurodegenerative diseases, including but not limited to Parkinson's disease, Alzheimer's disease and cerebral ischemia.

[0013] This kit enhances brain drug penetration by using Tween 80-coated SC79 or 740YP liposomes, and sequentially administers macromolecular peptides or macromolecular peptide brain-targeted drug delivery systems to enhance the intracerebral transport efficiency of macromolecular peptides or macromolecular peptide brain-targeted drug delivery systems. Compared with free SC79 or 740YP combined therapy, the expression of tyrosine hydroxylase and dopamine in PD mice in the Tween 80-coated SC79 or 740YP liposome group is higher, and motor symptoms are better restored, achieving a better effect in treating Parkinson's disease.

[0014] The present invention found that the use of Tween 80-coated SC79 liposomes or Tween 80-coated 740YP liposomes can down-regulate the expression of tight junction protein Claudin-5, increase the permeability of the blood-brain barrier, and thus enhance the brain transport efficiency of macromolecular polypeptides or brain-targeted macromolecular polypeptide delivery systems, especially enhance the brain entry efficiency of Tween 80-modified glial cell-derived neurotrophic factor liposomes and exenatide liposomes, and significantly improve the therapeutic effect of Parkinson's disease and Alzheimer's disease. To this end, the present invention has developed a kit, a brain-targeted small molecule compound delivery system increases brain permeability, and sequentially administers macromolecular polypeptides or brain-targeted macromolecular polypeptide delivery systems to improve the efficacy of neurodegenerative diseases.

[0015] The invention provides a kit for promoting drug brain penetration and neuron repair. Tween 80-coated SC79 liposomes or Tween 80-coated 740YP liposomes can enhance brain permeability, and sequential administration of macromolecular polypeptides or macromolecular polypeptide brain-targeted drug delivery systems can enhance the brain transport efficiency of macromolecular polypeptides or macromolecular polypeptide brain-targeted drug delivery systems, and can particularly significantly enhance the brain transport efficiency of Tween 80-modified liposomes carrying glial cell-derived neurotrophic factor or exenatide. Compared with the existing first-line clinical treatment methods, the advantages of the present invention for the treatment of neurodegenerative diseases, especially Parkinson's disease, are: 1) It can improve the in vivo stability of large molecular polypeptides and prolong their in vivo half-life; 2) Open the blood-brain barrier and significantly increase the amount of large molecular polypeptides entering the brain parenchyma; 3) Open the blood-brain barrier and significantly increase the amount of large molecular polypeptide brain-targeted drug delivery system entering the brain parenchyma; 4) Increase the accumulation of SC79 in the brain and play a greater role in opening the blood-brain barrier; 5) Compared with the international advanced treatment method of intracranial administration, the intravenous administration route is convenient and fast, which improves patients' medication compliance. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1: DiD-encapsulated liposomes and Tween 80 (PS 80)-modified liposomes were incubated with bEnd.3 cells for 1, 4, 8, 12, and 24 hours, respectively, and then the cellular uptake was observed using a laser confocal microscope.

[0017] Figure 2 Dir-encapsulated liposomes and Tween 80 (PS 80)-modified liposomes were intravenously administered to C57BL / 6 mice at a dose of 5 mg / kg. Mice were euthanized 4, 12, and 24 hours after injection, and brains were collected for small animal in vivo imaging.

[0018] Figure 3 SC79 or PS80-liposomes / SC79 were added to the physiological blood-brain barrier model chamber and incubated for 24 hours. Then, 0.5 mg / ml of 10 KDa, 40 KDa and 70 KDa FITC-dextran were added to the chamber respectively. The incubation was continued for 4 hours at 37°C and 5% carbon dioxide. The culture medium in the lower chamber was collected and the concentration of FITC-dextran leaked into the lower chamber was detected by a fluorescence spectrophotometer. n=3.

[0019] Figure 4 bEnd.3 cells were collected at 3×10 5 The cells were seeded at a density of 100 cells / well in a 24-well plate with a glass disc (1 cm in diameter) placed at the bottom and incubated at 37°C and 5% carbon dioxide for 7 days. SC79 or PS80-liposomes / SC79 were added to the above physiological blood-brain barrier model and incubated for 24 hours. The expression of tight junction protein Claudin-5 was observed by immunofluorescence.

[0020] Figure 5 :Cellular pharmacodynamics of each therapeutic agent, SH-SY5Y cells treated with MPP + Induced into PD cell model, Ctrl group as positive control, PD group as negative control, the other groups were given exenatide, SC79+exenatide, liposomes / SC79+exenatide, PS80-liposomes / SC79+PS80-liposomes / exenatide, immunofluorescence was used to detect the expression of tyrosine hydroxylase. A is the confocal image result of each group, B is the semi-quantitative result of fluorescence intensity, n=3.

[0021] Figure 6: Cellular pharmacodynamics of each therapeutic preparation. SH-SY5Y cells were induced with Aβ to form an AD cell model. The Ctrl group was the positive control, the AD group was the negative control, and the other groups were given exenatide, 740YP+exenatide, liposomes / 740YP+exenatide, PS80-liposomes / 740YP+PS80-liposomes / exenatide, respectively. The expression of acetylcholinesterase was detected by immunofluorescence. A is the confocal image result of each group, and B is the semi-quantitative result of fluorescence intensity, n=3.

[0022] Figure 7 SC79 or PS80-liposomes / SC79 were injected into C57BL / 6 mice through the tail vein. 24 hours later, Evans blue (2% w / v, 8 ml / kg) solution was injected into the tail vein. After 4 hours of circulation, the intact brain was obtained by cardiac perfusion with PBS, and the distribution intensity of Evans blue in the brain tissue was qualitatively observed using a small animal in vivo imaging device.

[0023] Figure 8 SC79 or PS80-liposomes / SC79 were injected into C57BL / 6 mice through the tail vein. After 24 hours, the mice were perfused with PBS and 4% formaldehyde to obtain the intact brain. The intact brain was cut into small pieces through a brain mold. The small pieces were fixed with 2.5% glutaraldehyde and then with 1% osmium tetroxide. The pieces were dehydrated with different concentrations of alcohol and embedded in epoxy resin. Ultrathin sections were cut and stained with uranyl acetate and lead citrate, and the ultrastructure of the blood-brain barrier was observed by transmission electron microscopy.

[0024] Fig. 9 :Evaluation of mouse behavior - open field test, mice were placed in a 45 cm × 45 cm × 45 cm acrylic cube, allowed to explore freely for 10 minutes and the total distance, average speed, rest time and center area movement distance during the test were recorded. Figure A is the movement trajectory of mice in each group, and Figure B is the quantitative results of total movement distance (Distance in zone-total), average speed (Mean speed in zone-total), rest time (Time immobile in zone-total) and center area movement distance (Distance in zone-center), n = 5.

[0025] Fig.10:A is the behavioral evaluation of mice-fatigue rotating rod, the mice were placed on the rotating rod, and the time each mouse stayed on the rod was recorded at a constant speed (15rpm) and accelerated (accelerated rotation from 4rpm to 40rpm within 100 seconds), n=5; B is the behavioral evaluation of mice-pole climbing test, the mice were placed on a vertical metal rod with a rough surface (70 cm high, 1 cm diameter). The time required for the mouse to climb to the bottom of the rod (T-total) and turn around on the rod (T-turn) was recorded, n=5.

[0026] Fig.11 :Biochemical indexes of mice in each group were detected. On the 22nd day, the mice were anesthetized and the brains were removed. Fresh brain slices of 400 μm thickness were taken from the striatum (Cpu) and substantia nigra pars compacta (SNpc) using brain molds to measure dopamine (DA) content. Figure A shows the TH expression in the striatum of mice in each group; Figure B shows the TH expression in the substantia nigra pars compacta of mice in each group; Figure C shows the semi-quantitative content of the substantia nigra pars compacta of mice in each group on the left, n=4, and the content of DA in the striatum of mice in each group on the right, n=4; Figure D shows the protein imprint of TH expression in the striatum of mice in each group and its semi-quantitative ... DETAILED DESCRIPTION

[0027] The present invention is described in detail with reference to the embodiments and the accompanying drawings. It should be noted that the following embodiments are only for illustration and do not limit the protection scope of the present invention.

[0028] Example 1 Preparation of brain-targeted macromolecular polypeptide delivery system

[0029] 1. Preparation of Tween 80 modified GDNF liposome delivery system

[0030] Liposomes were prepared by thin film hydration method. 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or (2,3-dioleoyl-propyl)-trimethylammonium chloride (DOTAP) or 12-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 (DMG-PEG2000) were weighed and dissolved in chloroform at a mass ratio of 6:1, 4:1 and 2:1, respectively, and then the two were mixed together and placed in a rotary evaporator at 42°C to form a lipid film. The residual solvent was removed by vacuum evaporation for 2 hours. PBS containing 1 μg / ml mouse GDNF was added to the lipid film, and the mixture was sonicated in a water bath for 2 minutes. After that, the mixture was placed in a -80°C refrigerator for 3 minutes, 37°C water bath for 5 minutes, and vortexed for 30 seconds. The freeze-thaw cycle was repeated 5 times for better encapsulation of GDNF. Afterwards, the liposomes were added to an ultrafiltration centrifuge tube (MWCO=50KDa) and centrifuged at 4°C for 30 minutes to obtain liposomes encapsulating GDNF. The particle size and potential are shown in Table 1. The particle size is about 100 nm and the potential is positive.

[0031] Tween 80 was added to the above liposomes (w:w=3:1), and stirred at room temperature for 2 hours to obtain a Tween 80-modified liposome delivery system.

[0032] Table 1: Particle size and potential of each liposome measured by dynamic light scattering

[0033]

[0034]

[0035] Example 2: Study on the targeting properties of brain-targeted macromolecular peptide delivery system in vivo and in vitro

[0036] 1. In vitro blood-brain barrier targeting of Tween 80 modified GDNF liposome delivery system

[0037] bEnd.3 cells were used to evaluate the brain targeting ability of the above liposomes. Fluorescent dye DiD (w:w = 5%) was added to 1 mg / ml liposomes or Tween 80-modified liposomes, and the mixture was stirred at room temperature for 1 hour. The suspension was dialyzed in a dialysis membrane (MWCO = 300KDa) for 24 hours to remove unencapsulated DiD, thereby obtaining DiD-labeled liposomes. Cells were incubated with the above DiD-labeled liposomes (1 mg / ml) in 5% carbon dioxide at 37°C for 1, 4, 8, 12, and 24 hours, respectively, washed 3 times with PBS, fixed with 4% formaldehyde, and counterstained with DAPI for nuclei. Laser confocal microscopy was used to image cellular uptake.

[0038] The results are as follows Figure 1As shown, cells co-incubated with Tween 80-modified liposomes displayed stronger fluorescence, indicating superior brain targeting ability.

[0039] 2. In vivo blood-brain barrier targeting of Tween 80 modified GDNF liposome delivery system

[0040] Fluorescent dye Dir (w:w = 5%) was added to 5 mg / ml liposomes or Tween 80 modified liposomes, and the mixture was stirred at room temperature for 1 hour. The suspension was dialyzed in a dialysis membrane (MWCO = 300 KDa) for 24 hours to remove unencapsulated Dir, and Dir-labeled liposomes were obtained. The dose of 5 mg / kg was administered to C57BL / 6 mice by tail vein. Mice were euthanized 4, 12 and 24 hours after injection, and the brains were collected for small animal in vivo imaging.

[0041] The results are as follows Figure 2 As shown, Dir-labeled liposomes showed almost no fluorescent signal in the brain, indicating that the liposomes had poor brain targeting. At 4, 12, and 24 hours, Dir-labeled Tween 80-modified liposomes showed stronger fluorescent signals in the brain, indicating that Tween 80-modified liposomes had better brain targeting ability.

[0042] Example 3 Small molecule compound SC79 or PS80-liposomes / SC79 opens the blood-brain barrier and reduces Claudin-5 expression

[0043] 1. Construction of in vitro physiological blood-brain barrier model

[0044] Brain microvascular endothelial cells bEnd.3 were used as blood-brain barrier model cells, and 1×10 5 At a cell density of 100 cells / well, 0.5 mL of well-grown bEnd.3 cell suspension was inoculated into a 12-well Transwell culture plate chamber with a pore size of 0.4 μm, and 1.5 mL of fresh culture medium was added to the outer chamber. Fresh culture medium was replaced every other day and incubated for 15 days at 37°C and 5% carbon dioxide. When the cell transmembrane resistance value was greater than 170 ohm·cm2 (Ω·cm 2 ), it can be regarded as a physiological blood-brain barrier model.

[0045] 2. Study on the opening of blood-brain barrier by small molecule compound SC79 in vitro

[0046] SC79 (10 μM) or PS80-liposomes / SC79 (SC79 concentration was 10 μM) was added to the above-mentioned physiological blood-brain barrier model chamber and incubated for 24 hours. Subsequently, 0.5 mg / ml of 10 KDa, 40 KDa and 70 KDa FITC-dextran were added to the chamber respectively, and incubated for another 4 hours at 37°C and 5% carbon dioxide. The culture medium in the lower chamber was collected, and the concentration of FITC-dextran leaked into the lower chamber was detected by a fluorescence spectrophotometer.

[0047] The results are as follows Figure 3 As shown, compared with the control group, the amount of 10KDa and 40KDa FITC-dextran in the SC79 group was 2 times higher than that in the control group (P<0.0001, n=4), the amount of 10KDa FITC-dextran in the PS80-liposomes / SC79 group was 2.22 times higher than that in the control group (P<0.0001, n=4), the amount of 70KDa FITC-dextran in the SC79 group was 2.21 times higher than that in the control group (P<0.001, n=4), and the amount of PS80-liposomes / SC79 group was 2.54 times higher than that in the control group (P<0.001, n=4), indicating that SC79 or PS80-liposomes / SC79 opened the blood-brain barrier in vitro and allowed FITC-dextran to enter the lower chamber.

[0048] bEnd.3 cells were collected at 3×10 5 The cells were seeded at a density of 100 cells / well in a 24-well plate with a glass disc (1 cm in diameter) placed at the bottom. Fresh culture medium was replaced every other day and incubated for 7 days at 37°C and 5% carbon dioxide to form a physiological blood-brain barrier. SC79 (10 μM) or PS80-liposomes / SC79 (SC79 concentration was 10 μM) was added to the above-mentioned physiological blood-brain barrier model and incubated for 24 hours. The bottom glass disc was collected, washed 3 times with PBS, fixed with 4% formaldehyde, and blocked with 10% bovine serum albumin for 30 minutes. Claudin-5 primary antibody was added and incubated overnight at 4°C. Finally, fluorescently labeled secondary antibody was incubated for 1 hour, and cell nuclei were counterstained with DAPI. The expression of tight junction protein Claudin-5 was observed by laser confocal microscopy. The results are as follows Figure 3 shown.

[0049] according to Figure 4 The results show that SC79 or PS80-liposomes / SC79 reduce the expression of tight junction protein Claudin-5 and open the blood-brain barrier in vitro.

[0050] Example 4 In vitro pharmacodynamic study of the kit for promoting drug penetration into the brain and repairing neurons against Parkinson's disease and Alzheimer's disease

[0051] 1. In vitro anti-Parkinson's disease pharmacodynamics study

[0052] According to the method for constructing a physiological blood-brain barrier model in Example 3, a physiological blood-brain barrier was constructed; SH-SY5Y cells were cultured at 7×10 5 The cells were seeded at a density of 100 cells / well in a 12-well plate with a glass disc (1 cm in diameter) at the bottom. After 12 hours, 2 mM N-methyl-4-phenylpyridinium iodide was added to induce the PD cell model. After 12 hours, the cells were co-cultured with the physiological blood-brain barrier to construct a PD cell model. Exenatide, SC79+exenatide, liposomes / SC79+exenatide, PS80-liposomes / SC79+PS80-liposomes / exenatide were given. Each group was repeated 3 times, and the concentration of exenatide was 150 nM. After 24 hours, the glass disc at the bottom of the 12-well plate was collected and the expression level of tyrosine hydroxylase in SH-SY5Y cells was detected by immunofluorescence. The results are shown in Figure 5 shown.

[0053] according to Figure 5 As shown in the results, the semi-quantitative result of tyrosine hydroxylase expression of SH-SY5Y cells in PD group was 625.18 (mean fluorescence intensity), the semi-quantitative result of tyrosine hydroxylase expression of SH-SY5Y cells in exenatide group was 575.66, the semi-quantitative result of tyrosine hydroxylase expression of SH-SY5Y cells in SC79+exenatide group was 780.74, which was 1.25 times that of PD group (P<0.05, n=3), the semi-quantitative result of tyrosine hydroxylase expression of SH-SY5Y cells in liposomes / SC79+exenatide group was 1334.43, which was 2.13 times that of PD group (P<0.01, n=3), and the semi-quantitative result of tyrosine hydroxylase expression of SH-SY5Y cells in PS80-liposomes / SC79+PS80-liposomes / exenatide group was 1672.21, which was 2.67 times that of PD group (P<0.001, n=3). This indicates that SC79 opens the blood-brain barrier in vitro, and PS80-liposomes / SC79 enables SC79 to target the brain, further promoting the penetration of exenatide and its macromolecular delivery system into the brain and increasing the expression level of tyrosine hydroxylase.

[0054] 2. In vitro anti-Alzheimer's disease pharmacodynamics study

[0055] According to the method for constructing a physiological blood-brain barrier model in Example 3, a physiological blood-brain barrier was constructed; SH-SY5Y cells were cultured at 7×10 5The cells were seeded at a density of 100 cells / well in a 12-well plate with a glass disc (1 cm in diameter) at the bottom. After 12 hours, they were co-cultured with the physiological blood-brain barrier. 2.5 μL of 1 mg / ml Aβ stock solution was added to each well to induce the AD cell model. The control group did not add Aβ as a positive control, and the other wells were given PBS as a negative control. Exenatide, 740YP+Exenatide, liposomes / 740YP+Exenatide, PS80-liposomes / 740YP+PS80-liposomes / Exenatide, each group was repeated 3 times, and the concentration of Exenatide was 150 nM. After 24 hours, the glass disc at the bottom of the 12-well plate was collected and the acetylcholinesterase expression level of SH-SY5Y cells was detected by immunofluorescence. The results are shown in Figure 6 shown.

[0056] according to Figure 6 As shown in the results, the semi-quantitative result of acetylcholinesterase expression of SH-SY5Y cells in the AD group was 39.68 (mean fluorescence intensity), the semi-quantitative result of acetylcholinesterase expression of SH-SY5Y cells in the exenatide group was 32.00, the semi-quantitative result of acetylcholinesterase expression of SH-SY5Y cells in the 740YP combined with exenatide group was 14.73, which was 0.37 times that of the AD group (P<0.001, n=3), the semi-quantitative result of acetylcholinesterase expression of SH-SY5Y cells in the liposomes / 740YP+exenatide group was 13.06, which was 0.33 times that of the AD group (P<0.001, n=3), and the semi-quantitative result of acetylcholinesterase expression of SH-SY5Y cells in the PS80-liposomes / 740YP+PS80-liposomes / exenatide group was 12.04, which was 0.30 times that of the AD group (P<0.001, n=3). This indicates that 740YP opens the blood-brain barrier in vitro, and PS80-liposomes / 740YP enables 740YP to be targeted to the brain, further promoting the penetration of exenatide and its macromolecular delivery system into the brain and increasing the expression level of acetylcholinesterase.

[0057] Example 5: Pharmacodynamic study on anti-Parkinson's disease in model animals of the kit for promoting drug penetration into the brain and repairing neurons

[0058] 1. SC79 or PS80-liposomes / SC79 promotes Evans blue penetration in the brain

[0059] Male C57BL / 6 (20±2g) were selected as model animals and SC79 (5mg / kg) or PS80-liposomes / SC79 were injected through the tail vein. 24 hours later, Evans blue (2% w / v, 8ml / kg) solution was injected through the tail vein. After 4 hours of circulation, the intact brain was obtained by cardiac perfusion with PBS, and the distribution intensity of Evans blue in the brain tissue was qualitatively observed using a small animal living imager.

[0060] The results are as follows Figure 7 As shown, SC79 can open the blood-brain barrier in vivo and significantly increase the penetration of Evans blue in the mouse brain. PS80-liposomes / SC79 targets SC79 to the brain, and the effect of opening the blood-brain barrier is more significant.

[0061] 2. Morphological and structural changes of SC79 or PS80-liposomes / SC79 in opening the blood-brain barrier in vivo

[0062] SC79 (5 mg / kg) or PS80-liposomes / SC79 were injected into C57BL / 6 by tail vein. After 24 hours, the whole brain was perfused with PBS and 4% formaldehyde. The whole brain was cut into small pieces through a brain mold. The small pieces were fixed with 2.5% glutaraldehyde and then with 1% osmium tetroxide. They were dehydrated with different concentrations of alcohol and embedded in epoxy resin. Ultrathin sections were cut and stained with uranyl acetate and lead citrate and observed by transmission electron microscopy.

[0063] The results are as follows Figure 8 As shown, under physiological conditions, the tight junctions of the blood-brain barrier are intact and tightly bound together, showing a darker line under transmission electron microscopy. If the blood-brain barrier is open, the tight junctions are no longer tightly fitted, and loose gaps appear. Compared with the control group, SC79 and PS80-liposomes / SC79 significantly increased the gaps between tight junctions, indicating that SC79 or PS80-liposomes / SC79 open the tight junction proteins of the blood-brain barrier.

[0064] 3. Sequential administration of SC79 or PS80-liposomes / SC79 combined with Tween 80-modified GDNF liposome delivery system improves behavioral symptoms in Parkinson's mice

[0065] C57BL / 6 mice were intraperitoneally injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride 30 mg / kg for 7 consecutive days to induce PD model. PD mice were treated as follows: no intervention group, tail vein injection of GDNF liposomes, tail vein injection of Tween 80-modified GDNF liposomes, tail vein injection of SC79 (5 mg / kg) followed by Tween 80-modified GDNF liposomes 24 hours later, tail vein injection of PS80-liposomes / SC79 (5 mg / kg) followed by Tween 80-modified GDNF liposomes 24 hours later, each group of 5 mice, drug treatment lasted for 10 days, normal C57BL / 6 mice were used as positive control group, and then behavioral tests were performed on mice. Open field test was performed on the 17th day to evaluate the anxiety-like behavior and memory function of PD mice after drug treatment.

[0066] The results are as follows Fig. 9As shown, in the open field test, the total movement distance of the mice in the PD group was 16.24 m, the total movement distance of the mice in the Tween 80-modified GDNF liposome preparation group was 19.16 m, which was 1.18 times that of the PD group (P<0.01, n=5), the total movement distance of the mice in the SC79 combined with Tween 80-modified GDNF liposome preparation group was 23.58 m, which was 1.45 times that of the PD group (P<0.001, n=5), and the total movement distance of the mice in the PS80-liposomes / SC79 combined with Tween 80-modified GDNF liposome preparation group was 24.72 m, which was 1.52 times that of the PD group (P<0.001, n=5), indicating that the motor symptoms of the mice were improved; The immobility time of mice in the open field was 206.82s, that of mice in the Tween 80-modified GDNF liposome preparation group was 157.96s, which was 0.76 of that in the PD group (P<0.01, n=5), that of mice in the SC79 combined with Tween 80-modified GDNF liposome preparation group was 101.34s, which was 0.50 of that in the PD group (P<0.001, n=5), and that of mice in the PS80-liposomes / SC79 combined with Tween 80-modified GDNF liposome preparation group was 114.38s, which was 0.55 of that in the PD group (P<0.0001, n=5), indicating that the depressive symptoms of mice were improved; the movement distance of mice in the middle of the mine in the PD group was 0.68m, that of mice in the Tween 80-modified GDNF liposome preparation group was 1.09m, that of mice in the SC79 combined with Tween 80-modified GDNF liposome preparation group was The movement distance of mice in the liposome preparation group in the middle of the mine was 1.53m, which was 2.25 times that of the PD group (P<0.05, n=5). The movement distance of mice in the PS80-liposomes / SC79 combined with Tween 80-modified GDNF liposome preparation group in the middle of the mine was 1.58m, which was 2.32 times that of the PD group (P<0.01, n=5), indicating that the anxiety symptoms of mice were improved.

[0067] On day 19, the fatigue rotarod test was used to explore the effect of drug treatment on the motor coordination of mice. Motor coordination is proportional to the time the mice stay on the rod. Fig.10A, In the accelerated rotation mode, the PD mice stayed on the rod for 9.00 s, the GDNF liposome group stayed for 13.50 s, which was 1.50 times that of the PD mice (P<0.05, n=5), the Tween 80-modified GDNF liposome group stayed for 13.00 s, which was 1.44 times that of the PD mice (P<0.05, n=5), the SC79 combined with Tween 80-modified GDNF liposome group stayed for 16.00 s, which was 1.78 times that of the PD mice (P<0.01, n=5), and the PS80-liposomes / SC79 combined with Tween 80-modified GDNF liposome group stayed for 17.20 s, which was 1.50 times that of the PD mice (P<0.05, n=5). In the uniform rotation mode, the time that the PD group mice stayed on the rod was 26.00 s, the GDNF liposome group stayed on the rod was 26.80 s, the Tween 80-modified GDNF liposome group stayed on the rod was 33.00 s, which was 1.27 times that of the PD group mice (P<0.05, n=5), the SC79 combined with Tween 80-modified GDNF liposome group stayed on the rod was 43.80 s, which was 1.68 times that of the PD group mice (P<0.0001, n=5), and the PS80-liposomes / SC79 combined with Tween 80-modified GDNF liposome group stayed on the rod was 45.00 s, which was 1.73 times that of the PD group mice (P<0.0001, n=5), indicating that the motor coordination of the mice was improved.

[0068] On day 21, the pole climbing test was used to explore the effect of drug treatment on motor delay in mice. The mice were placed on a 70 cm long metal pole, and the time they took to climb from the top of the pole to the bottom (T-total) and to turn around on the pole (T-turn) was calculated. Fig.10B, The T-Total required for PD mice was 11.60s, that for GDNF liposome group was 10.90s, the residence time of Tween 80-modified GDNF liposome group was 9.00s, which was 0.78 of that of PD mice (P<0.05, n=5), and the residence time of SC79 combined with Tween 80-modified GDNF liposome group was 7.12s, which was 0.61 of that of PD mice (P<0.01, n=5). The residence time of the GDNF liposomes group modified by PS80-liposomes / SC79 combined with Tween 80 was 6.58 s, which was 0.57 of that of the PD group mice (P<0.001, n=5); the T-Turn required for the PD group mice was 24.60 s, that of the GDNF liposomes group was 23.24 s, that of the GDNF liposomes group modified by Tween 80 was 21.70 s, that of the GDNF liposomes group modified by SC79 combined with Tween 80 was 15.22 s, which was 0.62 of that of the PD group mice (P<0.0001, n=5), and that of the GDNF liposomes group modified by PS80-liposomes / SC79 combined with Tween 80 was 15.08 s, which was 0.61 of that of the PD group mice (P<0.0001, n=5), indicating that each preparation group improved the bradykinesia of mice.

[0069] 5. Sequential administration of SC79 combined with Tween 80-modified GDNF liposome delivery system improves biochemical indicators of Parkinson's mice

[0070] On the 22nd day, the mice in the above groups were anesthetized and their brains were removed. Fresh brain slices with a thickness of 400 μm were obtained from the striatum (Cpu) and substantia nigra pars compacta (SNpc) using a brain mold to detect the dopamine (DA) content. Fig.11 As shown in A and B, the typical biochemical characteristics of PD mice are the significant decrease in TH expression in the striatum and substantia nigra. Among the treatment groups, the mice in the PS80-liposomes / SC79 combined with Tween 80 modified GDNF liposome preparation group had the highest TH expression.

[0071] like Fig.11As shown in C, the DA content expressed in the substantia nigra compacta of PD mice was 39.55, and that in the GDNF liposome group modified with Tween 80 was 62.03, which was 1.57 times that of PD mice (P<0.01, n=5); that in the GDNF liposome group modified with SC79 and Tween 80 was 78.03, which was 1.97 times that of PD mice (P<0.001, n=5); and that in the GDNF liposome group modified with PS80-liposomes / SC79 and Tween 80 was 83.48, which was 2.11 times that of PD mice (P<0.001, n=5). The DA content expressed in the striatum of PD mice was 29.84, and that in the GDNF liposome group was 48.70, which was 1.63 times that of PD mice (P<0.01, The DA content of the GDNF liposomes group modified by SC79 and Tween 80 was 65.88, which was 2.21 times that of the PD group mice (P<0.001, n=5). The DA content of the GDNF liposomes group modified by PS80-liposomes / SC79 and Tween 80 was 73.04, which was 2.45 times that of the PD group mice (P<0.0001, n=5).

[0072] The results showed that Tween 80-modified GDNF liposomes could increase the expression of tyrosine hydroxylase and dopamine, preventing further degeneration of the disease. Sequential administration of SC79 could open the blood-brain barrier. Brain-targeted SC79 liposomes further improved the brain entry efficiency of the large-molecule peptide brain-targeted drug delivery system, increased the drug concentration in the lesion site in the brain, alleviated neuronal degeneration in Parkinson's disease, and significantly enhanced the therapeutic effect.

[0073] Example 6 Industrial Applicability

[0074] According to the present invention, a kit for promoting drug brain penetration and neuron repair can be provided, which can promote the entry of macromolecular polypeptides or brain-targeted macromolecular polypeptide delivery systems into the brain, and in particular, can enhance the transport efficiency of Tween 80-modified liposomes loaded with glial cell-derived neurotrophic factor or exenatide into the brain. By combining the blood-brain barrier permeability regulator with macromolecular polypeptides or macromolecular polypeptide brain-targeted drug delivery systems, the transport efficiency of macromolecular polypeptides into the brain can be enhanced, and the therapeutic effect on neurodegenerative diseases can be improved, with significantly superior technical effects. Therefore, the present invention has great practicality in the field of medicine.

Claims

1. Use of a kit for promoting drug penetration into the brain and repairing neurons in the preparation of drugs for treating neurodegenerative diseases, characterized in that: The kit is composed of a brain-targeted small molecule compound delivery system and a macromolecular polypeptide delivery system for enhancing brain penetration; The brain-targeted small molecule compound delivery system for enhancing brain penetration is SC79 liposomes, 740YP liposomes, Tween 80-coated SC79 liposomes or Tween 80-coated 740YP liposomes, and the liposomes are composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine or (2,3-dioleoyl-propyl)-trimethylammonium chloride or 12-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 and cholesterol in a mass ratio of 6:1-2:1; The macromolecular polypeptide delivery system is a macromolecular polypeptide liposome or a macromolecular polypeptide liposome modified with Tween 80, wherein the macromolecular polypeptide is exenatide or glial cell line-derived neurotrophic factor; the liposome is a combination of 1,2-dioleoyl-sn-glycero-3-phosphocholine or (2,3-dioleoyl-propyl)-trimethylammonium chloride or 12-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 and cholesterol in a mass ratio of 6:1-2:1; The neurodegenerative diseases are Parkinson's disease and Alzheimer's disease.

2. The use according to claim 1, characterized in that: The application is that the brain-targeted small molecule compound delivery system is used before the large molecule polypeptide delivery system, and the two are used sequentially to increase the amount of the latter entering the brain.

Citation Information

Patent Citations

  • Blood-brain barrier permeability regulating agent and application thereof

    CN111481677A